Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-carnitine in Rheumatoid Arthritis
NCT05792527Phase 3Recruiting
- Sponsor
- Tanta University
- Start
- Mar 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of levocarnitine in rheumatoid arthritis (RA) (2 arms), sponsored by Tanta University. Primary endpoints: Disease Activity Score 28-CRP at 3 months and Multidimensional Health Assessment Questionnaire at 3 months. Started Mar 2023; status: recruiting.
02
Drugs
levocarnitine
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05792527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05792527.